Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Animal models of calcific aortic valve disease.

Sider KL, Blaser MC, Simmons CA.

Int J Inflam. 2011;2011:364310. doi: 10.4061/2011/364310. Epub 2011 Aug 2.

2.

Calcific aortic valve stenosis: methods, models, and mechanisms.

Miller JD, Weiss RM, Heistad DD.

Circ Res. 2011 May 27;108(11):1392-412. doi: 10.1161/CIRCRESAHA.110.234138. Review.

3.

Diet-induced aortic valve disease in mice haploinsufficient for the Notch pathway effector RBPJK/CSL.

Nus M, MacGrogan D, Martínez-Poveda B, Benito Y, Casanova JC, Fernández-Avilés F, Bermejo J, de la Pompa JL.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1580-8. doi: 10.1161/ATVBAHA.111.227561. Epub 2011 Apr 14.

4.

Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves.

Wirrig EE, Hinton RB, Yutzey KE.

J Mol Cell Cardiol. 2011 Mar;50(3):561-9. doi: 10.1016/j.yjmcc.2010.12.005. Epub 2010 Dec 14.

5.

Klotho deficiency causes vascular calcification in chronic kidney disease.

Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW.

J Am Soc Nephrol. 2011 Jan;22(1):124-36. doi: 10.1681/ASN.2009121311. Epub 2010 Nov 29.

6.

The response to valve injury. A paradigm to understand the pathogenesis of heart valve disease.

Li C, Xu S, Gotlieb AI.

Cardiovasc Pathol. 2011 May-Jun;20(3):183-90. doi: 10.1016/j.carpath.2010.09.008. Epub 2010 Nov 13. Review.

PMID:
21075649
7.

Evidence for active regulation of pro-osteogenic signaling in advanced aortic valve disease.

Miller JD, Weiss RM, Serrano KM, Castaneda LE, Brooks RM, Zimmerman K, Heistad DD.

Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2482-6. doi: 10.1161/ATVBAHA.110.211029. Epub 2010 Sep 23. Erratum in: Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):e2.

8.

Heart valve structure and function in development and disease.

Hinton RB, Yutzey KE.

Annu Rev Physiol. 2011;73:29-46. doi: 10.1146/annurev-physiol-012110-142145. Review.

9.

Twist1 promotes heart valve cell proliferation and extracellular matrix gene expression during development in vivo and is expressed in human diseased aortic valves.

Chakraborty S, Wirrig EE, Hinton RB, Merrill WH, Spicer DB, Yutzey KE.

Dev Biol. 2010 Nov 1;347(1):167-79. doi: 10.1016/j.ydbio.2010.08.021. Epub 2010 Sep 6.

10.

Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents.

Hakuno D, Kimura N, Yoshioka M, Mukai M, Kimura T, Okada Y, Yozu R, Shukunami C, Hiraki Y, Kudo A, Ogawa S, Fukuda K.

J Clin Invest. 2010 Jul;120(7):2292-306. doi: 10.1172/JCI40973. Epub 2010 Jun 14. Erratum in: J Clin Invest. 2011 Jan 4;121(1):454.

11.

Reduced sox9 function promotes heart valve calcification phenotypes in vivo.

Peacock JD, Levay AK, Gillaspie DB, Tao G, Lincoln J.

Circ Res. 2010 Mar 5;106(4):712-9. doi: 10.1161/CIRCRESAHA.109.213702. Epub 2010 Jan 7.

12.

Valvular heart disease in osteogenesis imperfecta: presentation of a case and review of the literature.

Bonita RE, Cohen IS, Berko BA.

Echocardiography. 2010 Jan;27(1):69-73. doi: 10.1111/j.1540-8175.2009.00973.x. Epub 2009 Aug 31. Review.

PMID:
19725849
13.

Lack of periostin leads to suppression of Notch1 signaling and calcific aortic valve disease.

Tkatchenko TV, Moreno-Rodriguez RA, Conway SJ, Molkentin JD, Markwald RR, Tkatchenko AV.

Physiol Genomics. 2009 Nov 6;39(3):160-8. doi: 10.1152/physiolgenomics.00078.2009. Epub 2009 Sep 1.

14.

Notch1 represses osteogenic pathways in aortic valve cells.

Nigam V, Srivastava D.

J Mol Cell Cardiol. 2009 Dec;47(6):828-34. doi: 10.1016/j.yjmcc.2009.08.008. Epub 2009 Aug 18.

15.

Lowering plasma cholesterol levels halts progression of aortic valve disease in mice.

Miller JD, Weiss RM, Serrano KM, Brooks RM 2nd, Berry CJ, Zimmerman K, Young SG, Heistad DD.

Circulation. 2009 May 26;119(20):2693-701. doi: 10.1161/CIRCULATIONAHA.108.834614. Epub 2009 May 11.

16.

Relation of aortic valve and coronary artery calcium in patients with chronic kidney disease to the stage and etiology of the renal disease.

Piers LH, Touw HR, Gansevoort R, Franssen CF, Oudkerk M, Zijlstra F, Tio RA.

Am J Cardiol. 2009 May 15;103(10):1473-7. doi: 10.1016/j.amjcard.2009.01.396.

PMID:
19427449
17.

In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis.

Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R, Mohammadi M, Lanske B, Razzaque MS.

FASEB J. 2009 Feb;23(2):433-41. doi: 10.1096/fj.08-114397. Epub 2008 Oct 3.

18.

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators.

N Engl J Med. 2008 Sep 25;359(13):1343-56. doi: 10.1056/NEJMoa0804602. Epub 2008 Sep 2.

19.

Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves.

Gupta V, Barzilla JE, Mendez JS, Stephens EH, Lee EL, Collard CD, Laucirica R, Weigel PH, Grande-Allen KJ.

Cardiovasc Pathol. 2009 Jul-Aug;18(4):191-7. doi: 10.1016/j.carpath.2008.05.001. Epub 2008 Jul 14.

20.

Shared gene expression profiles in developing heart valves and osteoblast progenitor cells.

Chakraborty S, Cheek J, Sakthivel B, Aronow BJ, Yutzey KE.

Physiol Genomics. 2008 Sep 17;35(1):75-85. doi: 10.1152/physiolgenomics.90212.2008. Epub 2008 Jul 8.

Supplemental Content

Support Center